Inhibitors of membranous adenylyl cyclases

Roland Seifert, Gerald H. Lushington, Tung Chung Mou, Andreas Gille, Stephen R. Sprang

Research output: Contribution to journalReview articlepeer-review

Abstract

Membranous adenylyl cyclases (mACs) constitute a family of nine isoforms with different expression patterns. Studies with mAC gene knockout mice provide evidence for the notion that AC isoforms play distinct (patho)physiological roles. Consequently, there is substantial interest in the development of isoform-selective mAC inhibitors. Here, we review the current literature on mAC inhibitors. Structurally diverse inhibitors targeting the catalytic site and allosteric sites (e.g. the diterpene site) have been identified. The catalytic site of mACs accommodates both purine and pyrimidine nucleotides, with a hydrophobic pocket constituting a major affinity-conferring domain for substituents at the 2′- and 3′-O-ribosyl position of nucleotides. BODIPY-forskolin stimulates ACs 1 and 5 but inhibits AC2. However, so far, no inhibitor has been examined at all mAC isoforms, and data obtained with mAC inhibitors in intact cells have not always been interpreted cautiously enough. Future strategies for the development of the mAC inhibitor field are discussed critically.

Original languageEnglish
Pages (from-to)64-78
Number of pages15
JournalTrends in Pharmacological Sciences
Volume33
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Dive into the research topics of 'Inhibitors of membranous adenylyl cyclases'. Together they form a unique fingerprint.

Cite this